Abstract: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.

Abstract: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.

Abstract: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.

Abstract: Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs.

Abstract: A process for the preparation of prostaglandin compounds having the formula (I): wherein A is selected from the group consisting of C1-C6 alkyl groups; C7-C16 aralkyl groups wherein an aryl portion thereof is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; and (CH2)nOR? wherein n is an integer from 1 to 3 and R? represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; B is selected from OR? and NHR? wherein R? is C1-C6 alkyl groups; and represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

Abstract: A process for the preparation of prostaglandin compounds having the formula (I): wherein A is selected from the group consisting of C1-C6 alkyl groups; C7-C16 aralkyl groups wherein an aryl portion thereof is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; and (CH2)nOR? wherein n is an integer from 1 to 3 and R? represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; B is selected from OR? and NHR? wherein R? is C1-C6 alkyl groups; and represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

Abstract: A process for the preparation of prostaglandin compounds having the formula (I): wherein A is selected from the group consisting of C1-C6 alkyl groups; C7-C16 aralkyl groups wherein an aryl portion thereof is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; and (CH2)nOR? wherein n is an integer from 1 to 3 and R? represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl groups, halo and CF3; B is selected from OR? and NHR? wherein R? is C1-C6 alkyl groups; and represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: R1, R21, and R22 are independently an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. R2 is —NR4R5 or —N+≡C−. Alternatively, R1 and R2, taken together with the methine group to which they are bonded, are a moiety represented by the following structural formula: R3 is —NH2, —OH, —OC(O)H or —OR9. R5, R6 and R7 are independently —H or an amine protecting group. R8 is —H, —OH or —OR8. R9 is an alcohol protecting group. Also disclosed are methods of preparing these compounds.

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: 1

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: R1, R2, and R22 are independently an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. R2 is —NR4R5 or —N+≡C−. Alternatively, R1, and R2, taken together with the methine group to which they are bonded, are a moiety represented by the following structural formula: R3 is —NH2, —OH, —OC(O)H or —OR9. R5, R6 and R7 are independently —H or an amine protecting group. R8 is —H, —OH or —OR8. R9 is an alcohol protecting group. Also disclosed are methods of preparing these compounds.

Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: 1

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: 1

Abstract: Disclosed are novel compounds, and methods of making the same, represented by Structural Formula II, IX or XXVII: The compounds can be used to prepare combinatorial libraries based on a multicomponent Ugi reaction.

Abstract: The present invention relates to a method of preparing a 1-nitro-3-substituted-3-amino-2-propanol diastereomer represented by Structural Formula I: In Structural Formula I, R is an amine protecting group, and R1 is an amino acid side-chain, a protected amino acid side-chain, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl or a substituted or unsubstituted heteroaralkyl group. The method involves contacting a 1-nitro-3-substituted-3-amino-2-propanone with a reducing agent to form a mixture of 1-nitro-3-substituted-3-amino-2-propanol diastereomers. The 1-nitro-3-substituted-3-amino-2-propanol diastereomers are then separated by simulated moving bed chromatography to obtain one or more 1-nitro-3-substituted-3-amino-2-propanol diastereomer.

Abstract: Disclosed are novel compounds represented by Structural Formula II, IX or XXVIII: 1

Abstract: The present invention is a method of preparing a 3-aryl-1-indanamine represented by structural formula I: and physiologically acceptable salts thereof. In structure I, phenyl ring A can be unsubstituted or substituted with 1-4 substitutents. R1 is an aromatic group which can be substituted or unsubstituted. R2 and R3 are each, independently, hydrogen, an aliphantic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, an aralkyl group, or a substituted aralkyl group. Alternatively, R2 and R3, taken together with the nitrogen substitutent on the indan ring, form a non-aromatic ring system having 1-2 heteroatoms.

Abstract: Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.

Abstract: Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.